Key Capital Management’s Royalty Pharma RPRX Stock Holding History

Key Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.09K	Hold	53	–	–	﹤0.01%	540
2026 Q2	$2.97K	Buy	+53	New	+$2.76K	﹤0.01%	519

Other funds holding RPRX

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Key Capital Management's RPRX Position: Q3 2026 in Review

Key Capital Management held its Royalty Pharma (RPRX) position steady in Q3 2026 at 53 shares worth $3.09K. The position accounts for ﹤0.01% of the portfolio, ranked #540.

Key Capital Management first reported a position in RPRX in Q2 2026 and has held it in 2 quarters since. 573 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

Key Capital Management held 53 shares of Royalty Pharma worth $3.09K as of Q3 2026.
Key Capital Management left its Royalty Pharma share count unchanged in Q3 2026.
Royalty Pharma made up ﹤0.01% of Key Capital Management's portfolio in Q3 2026, its #540 holding.
Key Capital Management first reported a position in Royalty Pharma in Q2 2026 and has held it in 2 quarters since.
573 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Key Capital Management's 13F filing for Q3 2026, filed 3 Nov 2026.